AZN Stock Recent News
AZN LATEST HEADLINES
CAMBRIDGE, England--(BUSINESS WIRE)--Dato-DXd TL01 OS HLR.
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Topline overall survival (OS) results from the TROPION-Lung01 phase 3 trial, which previously met the dual primary endpoint of progression-free survival (PFS), numerically favored datopotamab deruxtecan (Dato-DXd) compared to docetaxel in the overall trial population of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior line of therapy. Survival results did not reach statistical sign.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of investigational amyloidosis therapies at the International Symposium on Amyloidosis (ISA), in Rochester, MN from May 26–30, 2024. Presentations will include a new subgroup analyses of the Phase 3 NEURO-TTRansform study of WAINUATM (eplontersen), which was approved by the US Food and Drug Administration (FDA) in.
CAMBRIDGE, Mass. , May 22, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM), ranging from target validation and antibody discovery through preclinical research, announced today that it has entered into a license agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) for preclinical monoclonal antibodies that will be used to create targeted therapies in oncology.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Astrazeneca (AZN) have what it takes?
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading portfolio and pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 to June 4, 2024. More than 100 abstracts will feature 25 approved and potential new medicines across the Company's diverse oncology portfolio and pipeline, including two late-breaking plenary presentations, a special late-breaking abstract session presentation and 1.
Shares in AstraZeneca PLC (LSE:AZN) were trading just off their all-time high as leading analysts provided a largely positive assessment of its growth plans, the highlight of which was a 2030 revenue target of $80 billion - a 75% increase on last year's total. There were some reservations following the drugs giant's investor day hosted by CEO Pascal Soriot, notably around its aspirations to grow the operating profit margin to 35%.
Shares in AstraZeneca PLC (LSE:AZN) were trading just off their all-time high as leading analysts provided a largely positive assessment of its growth plans, the highlight of which was a 2030 revenue target of $80 billion - a 75% increase on last year's total. There were some reservations following the drugs giant's investor day hosted by CEO Pascal Soriot, notably around its aspirations to grow the operating profit margin to 35%.
AstraZeneca's (AZN) American depositary receipts (ADRs) rose over 2% to a record high Tuesday after the Anglo-Swedish drug maker announced what it called its “bold ambition” for future growth.
AstraZeneca (AZN) targets $80 billion in total revenues by 2030. It expects to launch 20 new medicines.